The content of this website has been produced in line with the BOSULIF® (bosutinib) Summary of Product Characteristics for Great Britain and Northern Ireland. For BOSULIF® (bosutinib) Prescribing Information Click here. Adverse event reporting information can be found at the bottom of the page.
BOSULIF has been tested in a large number of patients and demonstrates efficacy in a wide range of patient types
Patient cohorts (N = 574* including patients receiving ≥ 1 dose of BOSULIF)
Primary cohort: imatinib resistant
Sub-group: imatinib intolerant
IMI-R/I + dasatinib resistant (n=38)
IMI-R/I + dasatinib intolerant (n=50)
IMI-R/I + nilotinib resistant (n=26)
IMI-R/I + nilotinib intolerant (n=5)
Sub-group: Accelerated phase
Sub-group: Blast phase (n=64)
*Includes 24 patients who were Ph+ ALL.3
†Third- and fourth-line subgroups comprise patients with CP CML that were imatinib resistant or imatinib intolerant and ≥ 1 of the following: Dasatinib resistant or dasatinib intolerant, nilotinib resistant, nilotinib intolerant or resistant/intolerant to dasatinib and nilotinib.
Primary endpoint‡: 33% (95% CI, 27–40%) MCyR at 24 weeks in imatinib-resistant patients (n=200)1,5
Results show that the best cumulative response is either attained or maintained.
*Minimum follow-up period was 5 years (CP 2nd-line) or 4 years (CP 3rd-/4th-line and AP/BP).
Criteria used: Resistant mutation; medical history or evidence of prior TKI intolerance.
†Received ≥ 1 BOSULIF dose and had a valid baseline assessment for the corresponding endpoint.
‡In patients with CP imatinib-resistant CML and no previous TKI exposure other than imatinib.
AP, accelerated phase; BP, blast phase; CCyR, complete cytogenetic response; CI, confidence interval; CML, chronic myeloid leukaemia; CP, chronic phase; ELN; European LeukemiaNet, IMI-R/I; imatinib resistant or intolerant, MCyR, major cytogenetic response; TKI, tyrosine kinase inhibitor.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021